Lepodisiran
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| Other names | LY3819469; LY-3819469 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lepodisiran (LY3819469) is a small interfering RNA that was developed to reduce lipoprotein(a) in people at risk of cardiovascular disease. It was developed by Eli Lilly and Company.[1][2]
As of March 31 of 2025, company trials in phase 2 of randomized, double-blind, placebo-controlled study resulted in significant reduction of genetically inherited cardiovascular risk factors such as heart attacks, strokes, thrombosis, nearly 94% from baseline.[3]
